Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Work
Year: 2011
Type: article
Abstract: Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two phase 2 studies. We evaluated the... more
Source: New England Journal of Medicine
Institutions The University of Texas MD Anderson Cancer Center, The Ohio State University, Kyushu University, Hôpital Edouard Herriot, Cedars-Sinai Medical Center +9 more
Cites: 25
Cited by: 2,696
Related to: 10
FWCI: 186.3
Citation percentile (by year/subfield): 100
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze